

Disposal of own shares

Brussels (Belgium), 11 April 2022 – 20:00 (CEST) – Regulated information

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
01 April 2022	09:46:02	Stock Option Plan 2013	100	€ 48,69
01 April 2022	09:46:20	Stock Option Plan 2017	278	€ 72,71
04 April 2022	09:31:15	Stock Option Plan 2019	1.990	€ 76,09
04 April 2022	09:32:14	Stock Option Plan 2019	1.530	€ 76,09
04 April 2022	10:07:03	Stock Option Plan 2018	1.208	€ 66,18
04 April 2022	10:08:05	Stock Option Plan 2018	1.250	€ 66,18
04 April 2022	10:08:16	Stock Option Plan 2019	900	€ 76,09
04 April 2022	11:30:40	Stock Option Plan 2019	456	€ 76,56
04 April 2022	11:32:20	Stock Option Plan 2019	1.044	€ 76,09
04 April 2022	12:01:47	Stock Option Plan 2019	1.500	€ 76,09
04 April 2022	13:22:48	Stock Option Plan 2018	1.500	€ 66,18
04 April 2022	14:34:02	Stock Option Plan 2019	1.104	€ 76,09
04 April 2022	14:35:19	Stock Option Plan 2019	456	€ 76,56
04 April 2022	17:13:15	Stock Option Plan 2013	700	€ 48,69
05 April 2022	09:05:03	Stock Option Plan 2016	300	€ 67,24
05 April 2022	09:32:28	Stock Option Plan 2013	100	€ 48,69
05 April 2022	09:32:28	Stock Option Plan 2013	111	€ 49,80
05 April 2022	09:32:28	Stock Option Plan 2015	545	€ 67,35
05 April 2022	09:32:28	Stock Option Plan 2017	600	€ 70,26
05 April 2022	09:32:28	Stock Option Plan 2017	1.300	€ 70,26
05 April 2022	10:07:08	Stock Option Plan 2019	2.609	€ 76,09
05 April 2022	10:11:28	Stock Option Plan 2019	2.000	€ 76,09
05 April 2022	10:30:16	Stock Option Plan 2015	600	€ 67,35
05 April 2022	14:02:09	Stock Option Plan 2019	1.846	€ 76,09
05 April 2022	14:34:09	Stock Option Plan 2019	1.500	€ 76,09
05 April 2022	15:00:33	Stock Option Plan 2019	1.500	€ 76,09
05 April 2022	16:13:54	Stock Option Plan 2014	100	€ 58,12

05 April 2022	16:13:54	Stock Option Plan 2015	200	€ 67,35
06 April 2022	09:00:07	Stock Option Plan 2018	100	€ 66,18
06 April 2022	09:00:09	Stock Option Plan 2013	1.000	€ 48,69
06 April 2022	09:06:14	Stock Option Plan 2013	700	€ 48,69
06 April 2022	09:17:33	Stock Option Plan 2019	2.000	€ 76,09
06 April 2022	09:22:49	Stock Option Plan 2019	456	€ 76,56
06 April 2022	09:44:02	Stock Option Plan 2013	1.000	€ 48,69
06 April 2022	10:46:48	Stock Option Plan 2019	1.000	€ 76,09
06 April 2022	16:00:10	Stock Option Plan 2013	1.000	€ 48,69
07 April 2022	09:58:38	Stock Option Plan 2013	100	€ 48,69
07 April 2022	10:17:48	Stock Option Plan 2013	200	€ 48,69
07 April 2022	10:17:48	Stock Option Plan 2014	300	€ 58,12
07 April 2022	11:59:30	Stock Option Plan 2017	1.500	€ 70,26
07 April 2022	12:00:37	Stock Option Plan 2018	1.575	€ 66,18
07 April 2022	12:23:14	Stock Option Plan 2013	100	€ 48,69
07 April 2022	12:36:40	Stock Option Plan 2013	300	€ 48,69
07 April 2022	12:44:08	Stock Option Plan 2019	1.500	€ 76,09
07 April 2022	12:58:05	Stock Option Plan 2014	2.343	€ 58,12
07 April 2022	13:21:28	Stock Option Plan 2014	250	€ 58,12
07 April 2022	14:47:12	Stock Option Plan 2018	1.000	€ 66,18
07 April 2022	14:53:30	Stock Option Plan 2019	1.575	€ 76,09
07 April 2022	15:59:00	Stock Option Plan 2019	2.000	€ 76,09
07 April 2022	17:01:16	Stock Option Plan 2013	600	€ 48,69
07 April 2022	17:14:26	Stock Option Plan 2013	1.189	€ 48,69


In addition to these exercises, on 1 April 2022, in accordance with the vesting rules under its 2019 LTI plan, UCB SA/NV has delivered for free a total of 444 712 UCB shares OTC to 1 511 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 1 April 2022 was € 109.10.

This press release is available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations

Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com



UCB News

Corporate Communications

Laurent Schots

T+32 2 559 92 64

laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

